Her main concern is when they are offered as a first-line solution
Phase 2 MARITIME data showed 20.0% body weight reduction at 420mg monthly dose over 52 weeks , matching weekly semaglutide and tirzepatide efficacy from a once-monthly format
Rare but Serious Warnings Pancreatitis, or inflammation of the pancreas Gallbladder issues, including gallstones Severe allergic reactions Vision changes in people with type 2 diabetes Thyroid tumors, including cancer Severe stomach problems Kidney damage from dehydration Low blood sugar in people with type 2 diabetes Increased resting heart rate Food or liquid getting into the lungs during surgery Gastroparesis (stomach paralysis) While rare, these side effects are possible
doi: 10.1016/j.celrep.2019.05.010 22 BishtK.OkojieK
Use a new syringe for every injection
Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V